Results for tag: "Transthyretin Amyloidosis Drug"

Transthyretin Amyloidosis (ATTR) is a rare, progressive, and fatal genetic disorder that affects the central nervous system. It is caused by the accumulation of abnormal proteins in the body, which can lead to organ damage and failure. ATTR is most commonly treated with drugs that target the abnormal proteins, such as tafamidis and patisiran. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected. Transthyretin Amyloidosis Drug market is a rapidly growing segment of the Central Nervous System Drugs market. It is driven by the increasing prevalence of ATTR, as well as the development of new treatments and therapies. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for them increases. Some of the major companies in the Transthyretin Amyloidosis Drug market include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sanofi. These companies are actively developing new treatments and therapies for ATTR, and are expected to continue to lead the market in the coming years. Show Less Read more